Navigating CNS Involvement in Relapsed/Refractory Acute Lymphoblastic Leukemia: Outcomes with Brexucabtagene Autoleucel
Acute lymphoblastic leukemia (ALL) that returns after treatment, or doesn’t respond initially (relapsed/refractory or R/R ALL), presents a important challenge. Increasingly, clinicians are exploring CAR T-cell therapy – specifically brexucabtagene autoleucel – as a potential treatment option. However, the presence of leukemia in the central nervous system (CNS) adds another layer of complexity. This article delves into recent findings regarding the efficacy and safety of brexucabtagene autoleucel in patients with R/R ALL and CNS involvement, offering insights for both healthcare professionals and those impacted by this aggressive disease.
Understanding the Patient Population
Recent research focused on a cohort of patients receiving brexucabtagene autoleucel, revealing key demographic and disease characteristics. Notably, the overall patient population was predominantly male (99%). Furthermore, a substantial proportion of patients presented with philadelphia chromosome-positive (Ph+) disease (45.2%) compared to Ph-negative disease (35.5%).
Several patients also exhibited specific molecular mutations,including TP53,SLC16A3-NOTCH1,TP53/DNMT3A,and PPM1D/CDKN2A/MLL3. These genetic alterations can influence treatment response and disease progression, highlighting the importance of extensive molecular profiling.
Interestingly, patients without CNS involvement tended to be younger, with a median age of 46 years, and more frequently male (56.3%) with Ph-negative disease (54.4%). This suggests potential differences in disease biology and treatment approaches based on CNS status.
Relapse and survival Outcomes
The median follow-up period for all patients was 13.8 months. For those with CNS involvement, 12 experienced relapse after receiving brexucabtagene autoleucel, with a median time to relapse of approximately 100 days. Of these relapses, five occurred specifically within the CNS, sometimes alongside systemic disease. Others were found in the bone marrow (2 cases), outside the bone marrow (1 case), or the relapse site wasn’t clearly documented (4 cases).
The cumulative relapse rate at one year was 39% in the CNS group, slightly higher than the 35% observed in patients without CNS disease, though this difference wasn’t statistically significant (P = .54).
Looking at overall survival, 25.8% of patients in the CNS group and 35.4% in the non-CNS group unfortunately passed away. Within the CNS group, a significant portion (4 of 8) died without evidence of leukemia relapse. The causes of death included complications like cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and multi-organ failure.
Progression-Free Survival (PFS): The 6- and 12-month PFS rates in the CNS group were 57% (95% CI, 38%-73%) and 47% (95% CI, 29%-34%), respectively, with a median PFS of 263 days.
Overall Survival (OS): The 6- and 12-month OS rates in the CNS group were 84% (95% CI,65%-93%) and 76% (95% CI,57%-88%),respectively. Median OS wasn’t yet reached.
Importantly, there was no statistically significant difference in either PFS (P = .83) or OS (P = .14) between patients with and without CNS involvement.
What This Means for You and Your Care
These findings offer encouraging, albeit cautious, optimism. While CNS involvement presents unique challenges in R/R ALL, brexucabtagene autoleucel demonstrates potential benefit even in this complex patient population. You should discuss with your oncologist whether CAR T-cell therapy is a suitable option